

Script 1

By Krithika Subramanian, Ph.D.

Word count = 170

Swiss Study Confirms Efficacy of Direct-Acting Antivirals in Chronic Hepatitis C Treatment

Excellent Sustained Virological Response Rates Reported in Swiss CHC Patients Treated With DAAs

The American Association for the Study of Liver Diseases and the European Association for Study of Liver guidelines recommend direct-acting antiviral (DAA) treatment for most patients with chronic hepatitis C.¹⁻²

The efficacy of direct-acting antiviral treatment was demonstrated in a prospective/retrospective study, with an overall Sustained Virological Response (SVR) rate of 94% in CHC patients treated at three Swiss tertiary care centers between November 2013 and June 2016.³

Direct-acting antiviral treatment was particularly efficacious in patients with hepatitis C genotype 1.³ Patients with genotype 4 had the lowest SVR rates of 85%. Treatment failure occurred in 27% of the patients.

Based on their data, the authors stressed the importance of adopting international guidelines for DAA use in CHC treatment. The authors also predicted further improvements in outcomes following the approval of newer pan-genotypic direct-acting antivirals, such as the sofosbuvir/velpatasvir/voxilaprevir combination recently approved by the FDA.⁴

References

1. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. *J Hepatol.* 2015;63(1):199–236.
[http://www.journal-of-hepatology.eu/article/S0168-8278\(15\)00208-1/fulltext](http://www.journal-of-hepatology.eu/article/S0168-8278(15)00208-1/fulltext)
2. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD/IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. *Hepatology.* 2015;62(3):932–954.
<http://dx.doi.org/10.1002/hep.27950>
3. Bachofner J, Valli PV, Bergamin I, *et al.* Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland. The Swiss Hepatitis C Cohort Study. *Swiss Med Wkly.* 2018;148:w14560.
<https://smw.ch/article/doi/smw.2018.14560>
4. FDA approves Vosevi for Hepatitis C
<https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm567467.htm>